Drug Trial Radar · NCT06455202
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
976
Actual
Start
Jul 19, 2024
Primary completion
Aug 4, 2026
Study completion Jun 2027
Sponsor
- Lead sponsor
- Celldex TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
Conditions
- Chronic Spontaneous Urticaria
Interventions
barzolvolimabBiological
Subcutaneous Administration
Matching placeboBiological
Matching placebo Subcutaneous Administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline to Week 12 of UAS7 (Urticaria Activity Score)Time frame: From Day 1 (first dose) to Day 85 (Week 12)
Locations
245 sites in 22 countries. Site status is shown where the registry gives one.
Allervie Clinical Research - Cullman
Cullman, Alabama
Research Solutions of Arizona PC
Litchfield Park, Arizona
Medical Research of Arizona a division of Allergy, Asthma, & Immunology, Assoc. Ltd.
Scottsdale, Arizona
Center for Dermatology & Plastic Surgery
Scottsdale, Arizona
Kern Research, Inc.
Bakersfield, California
UCLA Clinical Trials Contracts & Strategic Relations
Los Angeles, California
California Allergy and Asthma Medical Group
Los Angeles, California
LA Universal Research Center, Inc.
Los Angeles, California
Allergy and Asthma Associates of Southern Cal
Mission Viejo, California
Huntington Asthma & Allergy Center
Pasadena, California
Apex Clinical Research
San Diego, California
WR-MCCR
San Diego, California
University Clinical Trials
San Diego, California
Clinical Science Institute
Santa Monica, California
Raffi Tachdjian MD, Inc
Santa Monica, California
Clarity Dermatology, PLLC
Castle Rock, Colorado
Asthma and Allergy Associates
Colorado Springs, Colorado
Driven Research LLC
Coral Gables, Florida
Palm Beach Dermatology Group
Delray Beach, Florida
Dolphin Medical Research
Doral, Florida
South FL Clinical Research LLC
Miami, Florida
Dade Florida Clinical Research Center
Miami, Florida
Deluxe Health Center
Miami Lakes, Florida
Revival Clinical Research
Orlando, Florida
International Clinical Research - FL LLC
Sanford, Florida
D&H Tamarac Research Center, LLC
Tamarac, Florida
Advanced Clinical Research Institute (ACRI) - Florida
Tampa, Florida
Deluxe Health Center
Tampa, Florida
MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research
Tampa, Florida
University of South Florida
Tampa, Florida
Olympian Clinical Research
Tampa, Florida
Lane Dermatology Research - Centricity - PPDS
Columbus, Georgia
Skin Care Physicians of Georgia
Macon, Georgia
Treasure Valley Medical Research
Boise, Idaho
Rush University Medical Center
Chicago, Illinois
Sneeze Wheeze and Itch Associates LLC
Normal, Illinois
The Indiana Clinical Trials Center, PC
Plainfield, Indiana
South Bend Clinic
South Bend, Indiana
University of Kansas Medical Center
Kansas City, Kansas
Equity Medical
Bowling Green, Kentucky
Showing 40 of 245 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.